Navigation Links
Phosphagenics Announces Positive Proof of Concept Results from,Studies Utilizing Company's Dermal Drug Delivery Technology

MELBOURNE, Australia, June 25, 2007 /PRNewswire-FirstCall/ -- Phosphagenics Limited (AIM: PSG) announced today positive results from pre-clinical studies of its TPM-02 dermal drug delivery technology formulated with retinoic acid, a leading topical treatment for severe acne and an active ingredient used in anti-aging cosmetics.

The proof of concept studies showed a three-fold increase in the amount of retinoic acid delivered into the skin when formulated with TPM-02 compared to a control formulation. Importantly, there was no retinoic acid detected in the bloodstream. TPM-02's ability to deliver an active ingredient to the dermis, the active layer of the skin, highlights the system's potential use in dermatologic and cosmetic products.

This study builds upon Phosphagenics' successes in delivering drugs, including insulin, through the skin without causing skin irritation, and further demonstrates that the TPM-02 technology can be utilized to deliver and hold an active ingredient in the skin, which is optimal in achieving maximum effectiveness from dermatological and cosmetic products.

"These proof of concept studies demonstrate the adaptability and flexibility of Phosphagenics' delivery technology, and we intend to leverage these results in pursuing opportunities in the dermatological and cosmetic fields," said Dr. Esra Ogru, Executive Vice President R&D at Phosphagenics. "The ability to deliver greater amounts of retinoic acid to the skin will produce more effective products for consumers, which is our objective in the areas of dermatology and cosmetics."

In addition to improving the dermal delivery of retinoic acid, Phosphagenics sees broader applications for its TPM-02 technology with additional pre-clinical studies showing potential in the dermal delivery of other compounds, such as coenzyme Q10 (CoQ10) and omega-3 fatty acids.

About Phosphagenics Limited

Phospha genics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. The Company's core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms. Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market (PSG). An ADR -- Level 1 program has been established in the US with the Bank of New York (PPGNY) for US investors to trade in Phosphagenics' stock on the "over-the-counter" market.

For more information, please visit Phosphagenics' web site at http://www.phosphagenics.com

CONTACT: Company, Dr. Esra Ogru, Executive Vice President Research &Development, +1-646-706-2155, or Harry Rosen, President and CEO,+1-646-715-3581, both of Phosphagenics Limited; or U.S. Investors andMedia, Brian Ritchie or Evan Smith, of FD, +1-212-850-5600, forPhosphagenics Limited

Web site: http://www.phosphagenics.com/

Ticker Symbol: (NASDAQ-OTCBB:PPGNY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance and Financial ... financial preparation services, is providing an update on a charitable event that began ... Rescue is a locally recognized nonprofit that provides shelter and care for animals ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
Breaking Medicine News(10 mins):